| Advancing targeted protein degradation for cancer therapy B Dale, M Cheng, KS Park, HÜ Kaniskan, Y Xiong, J Jin Nature Reviews Cancer 21 (10), 638-654, 2021 | 290 | 2021 |
| Inhibitors of protein methyltransferases and demethylases HU Kaniskan, ML Martini, J Jin Chemical reviews 118 (3), 989-1068, 2018 | 272 | 2018 |
| Light-induced control of protein destruction by opto-PROTAC J Liu, H Chen, L Ma, Z He, D Wang, Y Liu, Q Lin, T Zhang, N Gray, ... Science advances 6 (8), eaay5154, 2020 | 246 | 2020 |
| A potent, selective, and cell-active inhibitor of human type I protein arginine methyltransferases MS Eram, Y Shen, MM Szewczyk, H Wu, G Senisterra, F Li, KV Butler, ... ACS chemical biology 11 (3), 772-781, 2016 | 234 | 2016 |
| Artificial intelligence and machine learning‐aided drug discovery in central nervous system diseases: State‐of‐the‐arts and future directions S Vatansever, A Schlessinger, D Wacker, HÜ Kaniskan, J Jin, MM Zhou, ... Medicinal research reviews 41 (3), 1427-1473, 2021 | 167 | 2021 |
| Selective inhibitors of protein methyltransferases HU Kaniskan, KD Konze, J Jin Journal of medicinal chemistry 58 (4), 1596-1629, 2015 | 134 | 2015 |
| Cancer selective target degradation by folate-caged PROTACs J Liu, H Chen, Y Liu, Y Shen, F Meng, HU Kaniskan, J Jin, W Wei Journal of the American Chemical Society 143 (19), 7380-7387, 2021 | 132 | 2021 |
| TF-PROTACs enable targeted degradation of transcription factors J Liu, H Chen, HU Kaniskan, L Xie, X Chen, J Jin, W Wei Journal of the American Chemical Society 143 (23), 8902-8910, 2021 | 131 | 2021 |
| Epigenetics and beyond: targeting writers of protein lysine methylation to treat disease KP Bhat, H Ümit Kaniskan, J Jin, O Gozani Nature Reviews Drug Discovery 20 (4), 265-286, 2021 | 131 | 2021 |
| Transformative network modeling of multi-omics data reveals detailed circuits, key regulators, and potential therapeutics for Alzheimer’s disease M Wang, A Li, M Sekiya, ND Beckmann, X Quan, N Schrode, ... Neuron 109 (2), 257-272. e14, 2021 | 115 | 2021 |
| A potent, selective and cell‐active allosteric inhibitor of protein arginine methyltransferase 3 (PRMT3) HÜ Kaniskan, MM Szewczyk, Z Yu, MS Eram, X Yang, K Schmidt, X Luo, ... Angewandte Chemie 127 (17), 5255-5259, 2015 | 115 | 2015 |
| A chemical biology toolbox to study protein methyltransferases and epigenetic signaling S Scheer, S Ackloo, TS Medina, M Schapira, F Li, JA Ward, AM Lewis, ... Nature communications 10 (1), 19, 2019 | 109 | 2019 |
| Discovery of a potent, selective, and cell-active dual inhibitor of protein arginine methyltransferase 4 and protein arginine methyltransferase 6 Y Shen, MM Szewczyk, MS Eram, D Smil, HU Kaniskan, ... Journal of medicinal chemistry 59 (19), 9124-9139, 2016 | 78 | 2016 |
| Harnessing the E3 ligase KEAP1 for targeted protein degradation J Wei, F Meng, KS Park, H Yim, J Velez, P Kumar, L Wang, L Xie, H Chen, ... Journal of the American Chemical Society 143 (37), 15073-15083, 2021 | 75 | 2021 |
| A selective WDR5 degrader inhibits acute myeloid leukemia in patient-derived mouse models X Yu, D Li, J Kottur, Y Shen, HS Kim, KS Park, YH Tsai, W Gong, J Wang, ... Science translational medicine 13 (613), eabj1578, 2021 | 71 | 2021 |
| Asymmetric multicomponent [C+ NC+ CC] synthesis of highly functionalized pyrrolidines catalyzed by silver (I) P Garner, HÜ Kaniskan, J Hu, WJ Youngs, M Panzner Organic letters 8 (17), 3647-3650, 2006 | 68 | 2006 |
| Chemical probes of histone lysine methyltransferases HU Kaniskan, J Jin ACS chemical biology 10 (1), 40-50, 2015 | 60 | 2015 |
| Structure–activity relationship studies for enhancer of zeste homologue 2 (EZH2) and enhancer of zeste homologue 1 (EZH1) inhibitors X Yang, F Li, KD Konze, J Meslamani, A Ma, PJ Brown, MM Zhou, ... Journal of medicinal chemistry 59 (16), 7617-7633, 2016 | 55 | 2016 |
| Analogs of tetrahydroisoquinoline natural products that inhibit cell migration and target galectin-3 outside of its carbohydrate-binding site AW Kahsai, J Cui, HU Kaniskan, PP Garner, G Fenteany Journal of biological chemistry 283 (36), 24534-24545, 2008 | 43 | 2008 |
| Recent progress in developing selective inhibitors of protein methyltransferases. HÜ Kaniskan, J Jin Current Opinion in Chemical Biology 39, 100-108, 2017 | 42 | 2017 |
